David Risinger
Stock Analyst at Leerink Partners
(3.58)
# 859
Out of 5,041 analysts
172
Total ratings
65.93%
Success rate
14.58%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Upgrades: Market Perform | $70 | $66.89 | +4.66% | 4 | Oct 14, 2025 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $458 → $456 | $422.63 | +7.90% | 5 | Sep 25, 2025 | |
| MTSR Metsera | Downgrades: Market Perform | $77 → $57 | $52.63 | +8.30% | 2 | Sep 24, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $18 → $22 | $18.12 | +21.41% | 5 | Sep 18, 2025 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $192.47 | -20.51% | 4 | May 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $575.69 | +44.87% | 9 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $228.25 | -9.75% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $43.83 | +66.55% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $17.39 | +296.78% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $7.33 | +118.28% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $27.13 | +62.18% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $41.60 | +267.79% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $14.14 | -29.28% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $34.00 | +38.24% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $292.89 | +8.57% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $24.14 | -54.43% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $821.04 | -44.22% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $120.74 | -24.63% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $24.67 | +94.57% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $9.05 | +308.84% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $138.18 | +27.37% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $10.31 | +55.19% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $21.50 | +109.30% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $6.38 | +448.59% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $21.77 | +88.33% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $146.39 | +18.86% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $36.85 | +38.40% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $19.02 | -57.94% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $87.18 | +2.09% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $10.42 | -71.21% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $30.04 | -46.74% | 9 | Apr 2, 2020 |
Halozyme Therapeutics
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $66.89
Upside: +4.66%
Vertex Pharmaceuticals
Sep 25, 2025
Upgrades: Outperform
Price Target: $458 → $456
Current: $422.63
Upside: +7.90%
Metsera
Sep 24, 2025
Downgrades: Market Perform
Price Target: $77 → $57
Current: $52.63
Upside: +8.30%
Roivant Sciences
Sep 18, 2025
Maintains: Outperform
Price Target: $18 → $22
Current: $18.12
Upside: +21.41%
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $192.47
Upside: -20.51%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $575.69
Upside: +44.87%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $228.25
Upside: -9.75%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $43.83
Upside: +66.55%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $17.39
Upside: +296.78%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $7.33
Upside: +118.28%
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $27.13
Upside: +62.18%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $41.60
Upside: +267.79%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $14.14
Upside: -29.28%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $34.00
Upside: +38.24%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $292.89
Upside: +8.57%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $24.14
Upside: -54.43%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $821.04
Upside: -44.22%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $120.74
Upside: -24.63%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $24.67
Upside: +94.57%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $9.05
Upside: +308.84%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $138.18
Upside: +27.37%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $10.31
Upside: +55.19%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $21.50
Upside: +109.30%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $6.38
Upside: +448.59%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $21.77
Upside: +88.33%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $146.39
Upside: +18.86%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $36.85
Upside: +38.40%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $19.02
Upside: -57.94%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $87.18
Upside: +2.09%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $10.42
Upside: -71.21%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $30.04
Upside: -46.74%